Evaluation of COVID-19 vaccine breakthrough infections among immunocompromised patients fully vaccinated with BNT162b2

References

• Covid.cdc.gov [Internet]. Atlanta (GA): Centers for Disease Control and Prevention. COVID data tracker [cited 2021 Sep 8]. Available from: https://covid.cdc.gov/covid-data-tracker/#trends_dailytrendscases.
   Google Scholar
• Fda.gov [Internet]. White Oak (MD): US Food and Drug Administration. Pfizer-BioNTech COVID-19 vaccine; 2021 August 30 [cited 2021 Sep 8]. Available from: https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccine.
   Google Scholar
• Fda.gov [Internet]. White Oak (MD): US Food and Drug Administration. Moderna COVID-19 vaccine; 2021 August 31 [cited 2021 Sep 8]. Available from: https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/moderna-covid-19-vaccine.
   Google Scholar
• Fda.gov [Internet]. White Oak (MD): US Food and Drug Administration. Janssen COVID-19 vaccine; 2021 August 31 [cited 2021 Sep 8]. Available from: https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/janssen-covid-19-vaccine.
   Google Scholar
• Polack FP, Thomas SJ, Kitchin N, C4591001 Clinical Trial Group, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383(27):2603–2615.
   PubMed Web of Science ®Google Scholar
• Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–416.
   PubMed Web of Science ®Google Scholar
• Fda.gov [Internet]. White Oak (MD): US Food and Drug Administration. FDA approves first COVID-19 vaccine; 2021 August 23 [cited 2021 Oct 28]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine.
   Google Scholar
• Cdc.gov [Internet]. Atlanta (GA): Centers for Disease Control and Prevention. COVID-19 vaccinations in the United States. [cited 2021 Sep 8]. Available from: https://covid.cdc.gov/covid-data-tracker/#vaccinations_vacc-people-onedose-pop-12yr.
   Google Scholar
• Cdc.gov [Internet]. Atlanta (GA): Centers for Disease Control and Prevention. Science brief: COVID-19 vaccines and vaccination. [updated 2021 May 27; cited 2021 Sep 8]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/fully-vaccinated-people.html.
   Google Scholar
• Haidar G, Mellors JW. Improving the outcomes of immunocompromised patients with coronavirus disease 2019. Clin Infect Dis. 2021;73(6):e1397–e1401.
   PubMed Web of Science ®Google Scholar
• Boyarsky BJ, Werbel WA, Avery RK, et al. Immunogenicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients. JAMA. 2021;325(17):1784–1786.
   PubMed Web of Science ®Google Scholar
• Yi SG, Knight RJ, Graviss EA, et al. Kidney transplant recipients rarely show an early antibody response following the first COVID-19 vaccine administration. Transplantation. 2021;105(7):e72–e73.
   PubMedGoogle Scholar
• Agha ME, Blake M, Chilleo C, et al. Suboptimal response to coronavirus disease 2019 messenger RNA vaccines in patients with hematologic malignancies: a need for vigilance in the postmasking era. Open Forum Infect Dis. 2021;8(7):ofab353.
   PubMed Web of Science ®Google Scholar
• Boyarsky BJ, Ruddy JA, Connolly CM, et al. Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases. Ann Rheum Dis. 2021;80(8):1098–1099.
   PubMed Web of Science ®Google Scholar
• Terpos E, Gavriatopoulou M, Ntanasis-Stathopoulos I, et al. The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment. Blood Cancer J. 2021;11(8):138.
   PubMed Web of Science ®Google Scholar
• Terpos E, Gavriatopoulou M, Fotiou D, et al. Poor neutralizing antibody responses in 132 patients with CLL, NHL and HL after vaccination against SARS-CoV-2: a prospective study. Cancers (Basel). 2021;13(17):4480.
   PubMed Web of Science ®Google Scholar
• Gavriatopoulou M, Terpos E, Ntanasis-Stathopoulos I, et al. Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2; a prospective study. Blood Adv. 2021;5(21):4398–4405.
   Web of Science ®Google Scholar
• Tenforde MW, Patel MM, Ginde AA, et al. Effectiveness of SARS-CoV-2 mRNA vaccines for preventing covid-19 hospitalizations in the United States. Clin Infect Dis. 2021;ciab687. DOI:https://doi.org/10.1093/cid/ciab687.
   Google Scholar
• Broh-Nissimov T, Orenbuch-Harroch E, Chowers M, et al. BNT162b2 vaccine breakthrough: Clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients. J Clin Microbiol Infect. 2021;27(11):1652–1657.
   Google Scholar
• Yelin I, Katz R, Herzel E, et al. Associations of the BNT162b2 COVID-19 vaccine effectiveness with patient age and comorbidities. medRxiv. 2021. Available from: https://doi.org/https://doi.org/10.1101/2021.03.16.21253686
   Google Scholar
• Whitaker HJ, Tsang RSM, Byford R, et al. Pfizer-BioNTech and oxford AstraZeneca COVID-19 vaccine effectiveness and immune response among individuals in clinical risk groups. Khub.net. 2021. Available from: https://khub.net/documents/135939561/430986542/RCGP+VE+riskgroups+paper.pdf/a6b54cd9-419d-9b63-e2bf-5dc796f5a91f
   Google Scholar
• Chodick G, Tene L, Rotem RS, et al. The effectiveness of the two-dose BNT162b2 vaccine: analysis of real-world data. Clin Infect Dis. 2021;ciab438. DOI:https://doi.org/10.1093/cid/ciab438
   Google Scholar
• Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384(15):1412–1423.
   PubMed Web of Science ®Google Scholar
• Barda N, Dagan N, Balicer RD. BNT162b2 mRNA covid-19 vaccine in a nationwide mass vaccination setting: reply. N Engl J Med. 2021;384:1970.
   PubMed Web of Science ®Google Scholar
• Young-Xu Y, Korves C, Powell EI, et al. Coverage and estimated effectiveness of mRNA COVID-19 vaccines among US Veterans . JAMA Netw Open. 2021;4(10):e2128391.
   PubMed Web of Science ®Google Scholar
• Khan N, Mahmud N. Effectiveness of SARS-CoV-2 vaccination in a veterans affairs cohort of patients with inflammatory bowel disease with diverse exposure to immunosuppressive medications. Gastroenterology. 2021;161(3):827–836.
   PubMed Web of Science ®Google Scholar
• Fda.gov [Internet]. White Oak (MD): US Food and Drug Administration. Coronavirus (COVID-19) update: FDA authorizes additional vaccine dose for certain immunocompromised individuals; 2021 August 12 [cited 2021 Sep 8]. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-vaccine-dose-certain-immunocompromised.
   Google Scholar
• Cdc.gov [Internet]. Atlanta (GA): Centers for Disease Control and Prevention. COVID-19 vaccines for moderately to severely immunocompromised people. [updated 2021 Sep 2; cited 2021 Sep 1]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/immuno.html.
   Google Scholar
• ClinicalTrials.gov. [Internet]. Bethesda (MD): US National Library of Medicine. COVID-19 vaccination and breakthrough infections among persons with immunocompromising conditions in the United States. [updated 2021 August 25 cited 2021 Sep 8]. Available from: https://clinicaltrials.gov/ct2/show/NCT05020145?term=05020145&draw=2&rank=1.
   Google Scholar
• Ama-assn.org [Internet]. Chicago (IL): American Medical Association. COVID-19 CPT coding and guidance; 2021 [cited 2021 Sep 8]. Available from: https://www.ama-assn.org/find-covid-19-vaccine-codes.
   Google Scholar
• Cdc.gov [Internet]. Atlanta (GA): Centers for Disease Control and Prevention. Interim clinical considerations for use of COVID-19 vaccines currently authorized in the United States. [updated 2021 Aug 31; cited 2021 Sep 8]. Available from: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html.
   Google Scholar
• Greenberg JA, Hohmann SF, Hall JB, et al. Validation of a method to identify immunocompromised patients with severe sepsis in administrative databases. Ann Am Thorac Soc. 2016;13(2):253–258.
   PubMed Web of Science ®Google Scholar
• Patel M, Chen J, Kim S, et al. Analysis of MarketScan data for immunosuppressive conditions and hospitalizations for acute respiratory illness, United States. Emerg Infect Dis. 2020;26(8):1720–1730.
   PubMed Web of Science ®Google Scholar
• Hughes K, Middleton DB, Nowalk MP, et al. Effectiveness of influenza vaccine for preventing laboratory-confirmed influenza hospitalizations in immunocompromised adults. Clin Infect Dis. 2021;ciaa1927. DOI:https://doi.org/10.1093/cid/ciaa1927
   Google Scholar
• Cdc.gov [Internet]. Atlanta (GA): Centers for Disease Control and Prevention: Advisory Committee on Immunization Practices COVID-19: people with certain medical conditions. [updated 2021 August 20; cited 2021 Sep 8]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html.
   Google Scholar
• Sentinelinitiative.org [Internet]. White Oak (MD): US Food and Drug Administration. Sentinel initiative: master protocol development: COVID-19 natural history; 2020 October 13 [cited 2021 Sep 8]. Available from: https://www.sentinelinitiative.org/methods-data-tools/methods/master-protocol-development-covid-19-natural-history.
   Google Scholar
• Von Elm E, Altman DG, Egger M, Equator Network [Internet], et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. [updated 2019 Oct 22; cited 2021 Sep 8]. Available from: https://www.equator-network.org/reporting-guidelines/strobe/.
   Google Scholar
• Chemaitelly H, Tang P, Hasan MR, et al. Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar. N Engl J Med. 2021;NEJMoa2114114. DOI:https://doi.org/10.1056/NEJMoa2114114
   Google Scholar
• Cdc.gov [Internet]. Atlanta (GA): Centers for Disease Control and Prevention. COVID-19 vaccine breakthrough case investigation and reporting. [updated 2021 Sep 1; cited 2021 Sep 8]. Available from: https://www.cdc.gov/vaccines/covid-19/health-departments/breakthrough-cases.html.
   Google Scholar
• Bar-On YM, Goldberg Y, Mandel M, et al. Protection of BNT162b2 vaccine booster against covid-19 in Israel. N Engl J Med. 2021;385(15):1393–1400.
   PubMed Web of Science ®Google Scholar
• Juthani PV, Gupta A, Borges KA, et al. Hospitalisation among vaccine breakthrough COVID-19 infections. Lancet Infect Dis. 2021;21(11):1485–1486.
   PubMed Web of Science ®Google Scholar